Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage.
Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage. “There may be a value in having a centralized guidance of treatments adapted to a particular patient,” said Dr Ribas. Dr Ribas also discussed the effect future agents being developed for the treatment of melanoma will have on the market. He says prices will be adapted to the benefit due to more competition in the marketplace.
“Perhaps there is some relief on the horizon in terms of pricing because of competition,” said Dr Weber. “Classic essence of capitalism.”
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen